Table 2. Characteristics of RA patients (n = 26).
| Baseline | Follow-up (12months) | |
|---|---|---|
| Age, years (SD) | 66.5 (9.2) | - |
| Female, n (%) | 20 (77) | - |
| Height, m (SD) | 1.56 (0.08) | - |
| Weight, kg (SD) | 54.5 (10.9) | - |
| BMI, kg/m2 (SD) | 22.3 (3.9) | - |
| Disease duration, months (SD) | 108.9 (143.6) | - |
| < 12 months, n (%) | 8 (31) | - |
| 12–120 months, n (%) | 10 (38) | - |
| > 120 months, n (%) | 8 (31) | - |
| CRP, mg/L (SD) | 0.69 (0.89) | 0.11 (0.15) |
| ESR, mm/h (SD) | 33.9 (23.0) | 15.6 (11.3) a |
| RF-positive, n (%) | 21 (88)a | - |
| ACPA-positive, n (%) | 11 (50)b | - |
| DAS28-CRP (SD) | 3.7 (1.2) | 1.7 (0.8) |
| Use of MTX, n (%) | 14 (54) | - |
| Use of biologics, n (%) | 21 (81) | - |
| ETN, n (%) | 1 (4) | - |
| ADA, n (%) | 3 (12) | - |
| TCZ, n (%) | 4 (15) | - |
| ABT, n (%) | 12 (46) | - |
| CZP, n (%) | 1 (4) | - |
| Use of low-dose glucocorticoids, n (%) | 7 (27) | - |
All data are shown as mean and standard deviation (SD), or absolute number and percentage.
RA, rheumatoid arthritis; BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; ACPA, anticitrullinated protein antibodies; DAS28, Disease Activity Score 28; MTX, methotrexate; ETN, etanercept; ADA, adalimumab; TCZ, tocilizumab; ABT, abatacept; CZP, certolizumab.
a Values for two patients are missing
b Values for four patients are missing